



PROGRAMME

BIOLOGICAL NONPROLIFERATION AND INTERNATIONAL HEALTH SECURITY: PROMOTING COOPERATION

Thursday 12 – Sunday 15 June 2008

913th WILTON PARK CONFERENCE

in co-operation with the UK Global Partnership Programme

THURSDAY 12 JUNE

1300-1430 Buffet lunch available

1500-1515 **Welcome to Wilton Park and Introduction to the Conference**
Mark SMITH
Programme Director, Security and Defence, Wilton Park, Steyning

1515-1645 1 **DUAL-USE SCIENCE AND THE THREATS TO THE PUBLIC**
What and where are the risks to the public from dual-use science? What is the significance of novel and emerging diseases? How are these likely to affect the public, and to what degree?

Risks and benefits of dual-use science

Sir Roy ANDERSON
Professor of Infectious Disease Epidemiology, Imperial College, London; former Chief Scientific Adviser at MOD, London

1645-1730 Photograph and Tea

1730-1830 2 **SCIENCE TO SOLVE CURRENT AND FUTURE PROBLEMS**
Where have there been improvements in the study of disease and pathogenesis, and where next? How can vaccines and vaccine production be enhanced? What are the dual-use risks involved in vaccine research?

Tim BROOKS
Head, Novel and Dangerous Pathogens, UK Health Protection Agency, Salisbury

1900 Drinks Reception

FRIDAY 13 JUNE

0915-1045 3 **BTWC**

How can the BTWC contribute to health security? What is the contribution of the work programme; including awareness raising and education including codes of conduct? How do we improve communication and information sharing between States in support of this? What is the relationship with UNSCR 1540 and the CWC? How could we do more? How does the BTWC strength compare with that of other non-proliferation treaties and measures? What is the scope for assistance under the BTWC?

Georgi AVRANCHEV

Chairman of the 2008 BTWC, and Permanent Representative of the Republic of Macedonia to the United Nations Office, Geneva

John WALKER

Principal Research Officer, Arms Control and Disarmament Research Unit, Foreign and Commonwealth Office, London

1045-1115 Coffee

1115-1245 4 **COOPERATIVE HEALTH SECURITY**

What have been the improvements in detection, diagnosis, response and notification in disease surveillance on the local, national and global scales? What has been and are the future roles of international aid and development? How can we best coordinate and integrate international efforts to improve global health security? What are the opportunities in the FSU and elsewhere?

Ottorino COSIVI

Project Leader, Programme for Preparedness for Deliberate Epidemics, Department of Epidemic and Pandemic Alert Response, World Health Organisation, Geneva

Kendra CHITTENDEN

Team Leader, Bio Engagement Programs, International Security and Nonproliferation Bureau, Office of Cooperative Threat Reduction, US Department of State, Washington DC

1245-1515 Lunch

1515-1600 5 **INTERNATIONAL COOPERATION AND FUNDING**

Plenary presentations followed by discussions in breakout groups

Where is the Global Partnership at present and where should it move next in the area of biosafety and biosecurity? What is the role of the Global Partnership in biological non-proliferation?

Andy WEBER

Advisor for Threat Reduction Policy, Office of the Secretary of Defense, Arlington

What are the EU priorities in the areas of biological non-proliferation and health security? What are the sources of EU funding in these areas? How does and should the EU interact with near neighbours in these areas?

Bruno DUPRÉ

Policy Officer, Directorate General for External Relations, European Commission, Brussels

Zuzana SUTIAKOVA

Desk Officer for non-Proliferation, Council of the European Union, Brussels

What are the other sources of funding – governments, non-governmental organisations, foundations, industry?

Terry TAYLOR

Vice-President Global Health and Security, NTI and President International Council for the Life Sciences, International Council for the Life Sciences (ICLS), Washington DC

1700-1730 **Feedback/lessons learned (to Plenary)**

1730-1800 Tea

1800-1900 6 **CENSORSHIP OR PROLIFERATION?**
How do we manage the positive and negative (proliferation) aspects of scientific knowledge and information sharing?

Anne HARRINGTON

Director, Committee on International Security and Arms Control (CISAC) The National Academy of Sciences, Washington DC

John KEDDIE

Vice President, R&D Operations (Europe and International) & WW Environment, Health & Safety, GlaxoSmithKline, Harlow

1930 Dinner

SATURDAY 14 JUNE

0915-1100 7 **BIOSAFETY AND BIOSECURITY**
What are the consequences of inadequate biosafety and biosecurity measures, in both the immediate and long term on a variety of scales? How do these vary between government, academia and private industry? Would better lab practice be more relevant, rather than security vetting? How do we ensure confidence in the biosafety and biosecurity of other laboratories and laboratory networks?

Paul LOGAN

Head, Biological Agents Unit, UK Health and Safety Executive. Bootle

Heather SHEELEY

Manager of Safety, Centre for Emergency Preparedness and Response, Health Protection Agency, Salisbury

1100-1130 Coffee

1130-1200 8 **ROLE OF THE SCIENCE CENTRES: FUTURE STRATEGY**
Plenary presentations followed by discussions in breakout groups
What involvement and experience have we had with the science centres? How successful were the interactions? What are the benefits and/or drawbacks of the interactions? What are the future roles of the science centres? How is commercialisation likely to affect these? What is the role of host governments?

ISTC's Expanding Role in Biosafety & Biosecurity

Leo OWSIACKI

Deputy Executive Director for Global Security and Strategic Planning, International Science and Technology Center, Moscow

Finding Creative Solutions for Biological Non-Proliferation Programming: Canada's GPP and the Science Centres.

Jennifer KLENIEWSKI

Program Officer, Global Partnership Program, Foreign Affairs and International Trade Canada, Ottawa

1300-1330 **Feedback/lessons learned (to Plenary)**

1330-1530 Lunch

1530-1700 9 **IMPORTANCE OF PREPARING FOR OUTBREAKS**
What are the key procedures to have established? How should they be established, and by whom? Are we hampered by issues related to the transfer of strains and tissues? In an ideal world, how could these be overcome?

Tim BROOKS

Head, Novel and Dangerous Pathogens, UK Health Protection Agency, Salisbury

Paata IMNADZE

Director, National Centre for Disease Control & Public Health, Tbilisi

1700-1730 Tea

1730-1800 10 **CONCLUSIONS AND LESSONS LEARNED**

Mark SMITH

Wilton Park, Steyning

Anne HARRINGTON

Director, Committee on International Security and Arms Control (CISAC) US National Academy of Sciences, Washington DC

1900 Drinks
1930 Dinner

SUNDAY 15 JUNE

0915 Participants depart